Vol 31, No 3 (2024)
Original Article
Published online: 2022-06-09

open access

Page views 2449
Article views/downloads 902
Get Citation

Connect on Social Media

Connect on Social Media

Left atrial appendage thrombus in patients with atrial fibrillation who underwent oral anticoagulation

Jarosław Karwowski1, Jerzy Rekosz2, Renata Mączyńska-Mazuruk1, Anna Wiktorska2, Karol Wrzosek1, Wioletta Loska2, Katarzyna Szmarowska2, Mateusz Solecki2, Joanna Sumińska-Syska1, Mirosław Dłużniewski1
Pubmed: 35703043
Cardiol J 2024;31(3):461-471.

Abstract

Background: Electric cardioversion of atrial fibrillation (AF) is associated with an increased risk of embolism, with embolic material existing in the heart cavities. The initiation of oral anticoagulation therapy reduces the risk of thromboembolic events. The aims of this study were to evaluate the prevalence of left atrial appendage (LAA) thrombi in non-valvular AF, to compare vitamin K antagonists (VKAs) and non-vitamin K oral anticoagulants (NOACs) with respect to thrombus prevalence, and to evaluate the rate of LAA thrombus persistence on repeat transesophageal echocardiography (TEE) after treatment change.

Methods: We enrolled 160 consecutive AF patients who presented with an AF duration > 48 h and had undergone TEE before cardioversion.

Results: Left atrial appendage thrombus was observed in 12 (7.5%) patients, and spontaneous echo contrast 4 was observed in 19 (11.8%) patients; the incidence was similar between the NOAC and VKA groups (8.9% vs. 3.6% and 12.4% vs. 18.5 %, respectively). Among patients on NOAC, thrombus prevalence was detected in 8.4% of users of rivaroxaban, 8% of users of dabigatran, and 12.5% of users of apixaban.

Conclusions: The LAA thrombus developed in 7.5% of patients despite anticoagulation therapy, demonstrating similar prevalence rates among patients either on NOAC or VKA. Lower mean LAA flow velocity and a history of vascular disease were independent predictors of embolic material in the LAA. It seems that in the case of embolic materials in LAA under NOAC treatment, switching to VKA provides additional clinical benefit to the patients.

Article available in PDF format

View PDF Download PDF file

References

  1. Haim M, Hoshen M, Reges O, et al. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc. 2015; 4(1): e001486.
  2. Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med. 1995; 155(5): 469–473.
  3. Piwońska A, Piwoński J, Szcześniewska D, et al. Population prevalence of electrocardiographic abnormalities: results of the Polish WAW‑KARD study. Kardiol Pol. 2019; 77(9): 859–867.
  4. Airaksinen K, Grönberg T, Nuotio I, et al. Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish Cardioversion) study. J Am Coll Cardiol. 2013; 62(13): 1187–1192.
  5. Lip GY. Cardioversion of atrial fibrillation. Postgrad Med J. 1995; 71(838): 457–465.
  6. Arnold AZ, Mick MJ, Mazurek RP, et al. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J Am Coll Cardiol. 1992; 19(4): 851–855.
  7. Saeed M, Rahman A, Afzal A, et al. Role of transesophageal echocardiography guided cardioversion in patients with atrial fibrillation, previous left atrial thrombus and effective anticoagulation. Int J Cardiol. 2006; 113(3): 401–405.
  8. Fatkin D, Kuchar DL, Thorburn CW, et al. Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: evidence for "atrial stunning" as a mechanism of thromboembolic complications. J Am Coll Cardiol. 1994; 23(2): 307–316.
  9. Andrade JG, Macle L, Nattel S, et al. Contemporary atrial fibrillation management: a comparison of the current AHA/ACC/HRS, CCS, and ESC Guidelines. Can J Cardiol. 2017; 33(8): 965–976.
  10. Flaker G, Lopes RD, Al-Khatib SM, et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol. 2014; 63(11): 1082–1087.
  11. Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011; 123(2): 131–136.
  12. Cappato R, Ezekowitz MD, Klein AL, et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014; 35(47): 3346–3355.
  13. Goette A, Merino JL, Ezekowitz MD, et al. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet. 2016; 388(10055): 1995–2003.
  14. Ezekowitz MD, Pollack CV, Halperin JL, et al. Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. Eur Heart J. 2018; 39(32): 2959–2971.
  15. Reers S, Karanatsios G, Borowski M, et al. Frequency of atrial thrombus formation in patients with atrial fibrillation under treatment with non-vitamin K oral anticoagulants in comparison to vitamin K antagonists: a systematic review and meta-analysis. Eur J Med Res. 2018; 23(1): 49.
  16. Frenkel D, D'Amato SA, Al-Kazaz M, et al. Prevalence of left atrial thrombus detection by transesophageal echocardiography: a comparison of continuous non-vitamin k antagonist oral anticoagulant versus warfarin therapy in patients undergoing catheter ablation for atrial fibrillation. JACC Clin Electrophysiol. 2016; 2(3): 295–303.
  17. Kawabata M, Goya M, Sasaki T, et al. Left atrial appendage thrombi formation in japanese non-valvular atrial fibrillation patients during anticoagulation therapy: warfarin vs. direct oral anticoagulants. Circ J. 2017; 81(5): 645–651.
  18. Gorczyca I, Chrapek M, Jelonek O, et al. Left atrial appendage thrombus formation despite continuous non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation patients undergoing electrical cardioversion or catheter ablation: a comparison of dabigatran and rivaroxaban. Cardiol Res Pract. 2020; 2020: 1206402.
  19. Scherr D, Dalal D, Chilukuri K, et al. Incidence and predictors of left atrial thrombus prior to catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2009; 20(4): 379–384.
  20. Wallace TW, Atwater BD, Daubert JP, et al. Prevalence and clinical characteristics associated with left atrial appendage thrombus in fully anticoagulated patients undergoing catheter-directed atrial fibrillation ablation. J Cardiovasc Electrophysiol. 2010; 21(8): 849–852.
  21. Calvo N, Mont L, Vidal B, et al. Usefulness of transoesophageal echocardiography before circumferential pulmonary vein ablation in patients with atrial fibrillation: is it really mandatory? Europace. 2011; 13(4): 486–491.
  22. Zoppo F, Brandolino G, Berton A, et al. Predictors of left atrium appendage clot detection despite on-target warfarin prevention for atrial fibrillation. J Interv Card Electrophysiol. 2012; 35(2): 151–158.
  23. Budnik M, Gawałko M, Gorczyca I, et al. Risk of left atrial appendage thrombus in patients with atrial fibrillation and chronic kidney disease. Cardiol J. 2022; 29(2): 205–215.
  24. Conway DSG, Lip GYH. Comparison of outcomes of patients with symptomatic peripheral artery disease with and without atrial fibrillation (the West Birmingham Atrial Fibrillation Project). Am J Cardiol. 2004; 93(11): 1422–5, A10.
  25. Siu CW, Jim MH, Ho HH, et al. Transient atrial fibrillation complicating acute inferior myocardial infarction: implications for future risk of ischemic stroke. Chest. 2007; 132(1): 44–49.
  26. Lip GYH. Coronary artery disease and ischemic stroke in atrial fibrillation. Chest. 2007; 132(1): 8–10.
  27. Uz O, Atalay M, Doğan M, et al. The CHA2DS2-VASc score as a predictor of left atrial thrombus in patients with non-valvular atrial fibrillation. Med Princ Pract. 2014; 23(3): 234–238.
  28. Tang RB, Dong JZ, Liu XP, et al. Is CHA2DS2-VASc score a predictor of left atrial thrombus in patients with paroxysmal atrial fibrillation? Thromb Haemost. 2011; 105(6): 1107–1109.
  29. Yarmohammadi H, Varr BC, Puwanant S, et al. Role of CHADS2 score in evaluation of thromboembolic risk and mortality in patients with atrial fibrillation undergoing direct current cardioversion (from the ACUTE Trial Substudy). Am J Cardiol. 2012; 110(2): 222–226.
  30. Tsai LM, Lin LJ, Teng JK, et al. Prevalence and clinical significance of left atrial thrombus in nonrheumatic atrial fibrillation. Int J Cardiol. 1997; 58(2): 163–169.
  31. Kleemann T, Becker T, Strauss M, et al. Prevalence and clinical impact of left atrial thrombus and dense spontaneous echo contrast in patients with atrial fibrillation and low CHADS2 score. Eur J Echocardiogr. 2009; 10(3): 383–388.
  32. Zhao Y, Ji L, Liu J, et al. Intensity of left atrial spontaneous echo contrast as a correlate for stroke risk stratification in patients with nonvalvular atrial fibrillation. Sci Rep. 2016; 6: 27650.
  33. Ayirala S, Kumar S, O'Sullivan DM, et al. Echocardiographic predictors of left atrial appendage thrombus formation. J Am Soc Echocardiogr. 2011; 24(5): 499–505.
  34. Ozcan Cetin EH, Ozbay MB, Cetin MS, et al. A new risk model for the evaluation of the thromboembolic milieu in patients with atrial fibrillation: the PALSE score. Kardiol Pol. 2020; 78(7-8): 732–740.
  35. Lip G, Hammerstingl C, Marin F, et al. Left atrial thrombus resolution in atrial fibrillation or flutter: results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). Am Heart J. 2016; 178: 126–134.
  36. Stoddard MF, Singh P, Dawn B, et al. Left atrial thrombus predicts transient ischemic attack in patients with atrial fibrillation. Am Heart J. 2003; 145(4): 676–682.
  37. Stoddard MF, Dawkins PR, Prince CR, et al. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. J Am Coll Cardiol. 1995; 25(2): 452–459.